Effect of concomitant use of pentoxifylline and alpha-tocopherol with radiotherapy on the clinical outcome of patients with stage IIIB non-small cell lung cancer: A randomized prospective clinical trial

Medical Oncology

Volumn 23, Issue 2, 2006, Pages 185-189

  Misirlioglu, Cem H ^a   Erkal, Handan ^a   Elgin, Yesim ^a   Ugur, Isil ^a   Altundag, Kadri ^b,c  

^a ANKARA ONCOLOGY HOSPITAL   (Turkey)

^b HACETTEPE UNIVERSITY   (Turkey)

^c NONE   (United States)

Author keywords

Alpha tocopherol; Chemotherapy; Non small cell lung cancer, locally advanced; Pentoxifylline; Radiotherapy

Indexed keywords

ALPHA TOCOPHEROL; ANTINEOPLASTIC AGENT; PENTOXIFYLLINE;

ADULT; AGED; ARTICLE; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; DISEASE SEVERITY; DRUG EFFECT; DRUG HYPERSENSITIVITY; DRUG TREATMENT FAILURE; EXTERNAL BEAM RADIOTHERAPY; FEMALE; FOLLOW UP; HUMAN; LUNG INJURY; LUNG NON SMALL CELL CANCER; LYMPH NODE; MAJOR CLINICAL STUDY; MALE; METASTASIS; MULTIMODALITY CANCER THERAPY; NAUSEA AND VOMITING; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; RADIATION DOSE; RADIATION INJURY; RANDOMIZED CONTROLLED TRIAL; STATISTICAL SIGNIFICANCE; SURVIVAL RATE; SURVIVAL TIME; VITAMIN SUPPLEMENTATION;

ADULT; AGED; ALPHA-TOCOPHEROL; ANTIOXIDANTS; CARCINOMA, NON-SMALL-CELL LUNG; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; PENTOXIFYLLINE; PROSPECTIVE STUDIES; RADIATION-PROTECTIVE AGENTS; RADIOTHERAPY DOSAGE; SURVIVAL RATE;

EID: 33646872021     PISSN: 13570560     EISSN: None     Source Type: Journal    
DOI: 10.1385/MO:23:2:185     Document Type: Article

References (10)

1. Miller KL, Shafman TD, Marks LB. A practical approach to pulmonary risk assessment in the radiotherapy of lung cancer. Semin Radiat Oncol 2003; 13:333-345.
2. Dion MW, et al. Preliminary results of a pilot study of pentoxifylline in the treatment of late radiation soft tissue necrosis. Int J Radiat Oncol Biol Phys 1990; 19:401-407.
3. Delanian S, Lefaix J-L. The radiation-induced fibroatrophic process: therapeutic perspective via the antioxidant pathway. Radiother Oncol 2004; 73:119-131.
4. Vapuel P, Kelleher D, Thews O. Modulation of tumor oxygenation. Int J Radiat Oncol Biol Phys 1998; 42:843-848.
5. Vapuel P. The role of hypoxia-induced factors in tumor progression. Oncologist 2004; 9:10-17.
6. Lefaix J-L, et al. Striking regression of subcutaneous fibrosis induced by high doses of gamma rays using a combination of pentoxifylline and alpha-tocopherol: an experimental study. Int J Radiat Oncol Biol Phys 1999; 43:839-847.
7. Delanian S, Balla-Mekias S, Lefaix J-L. Striking regression of chronic radiotherapy damage in a clinical trial of combined pentoxifylline and tocopherol. J Clin Oncol 1999; 17:3283-3290.
8. Kim SH, Khil MS, Ryu S, Kim SJ. Enhancement of radiation response on human carcinoma cells in culture by pentoxifylline. Int J Radiat Oncol Biol Phys 1993; 25:61-65.
9. Lee I, Biaglow JE, Lee J, Cho MJ. Physiological mechanisms of radiation sensitization by pentoxifylline. Anticancer Res 2000; 20:4605-4609.
10. Kwon HC, et al. Effect of pentoxifylline on radiation response of non-small cell lung cancer: a phase III randomized multicenter trial. Radiother Oncol 2000; 56:175-179.